Item
2.01. Completion of Acquisition of Disposition of Assets.
Additional
form 10 information
Item
2.01(f) of Form 8-K states that if the predecessor registrant was a shell company, as Larkspur was immediately before the Business Combination,
then the registrant must disclose the information that would be required if the registrant were filing a general form for registration
of securities on Form 10. Accordingly, the Company is providing the information below that would be included in a Form 10 if the Company
were to file a Form 10. Please note that the information provided below relates to the Company following the consummation of the Business
Combination, unless otherwise specifically indicated or the context otherwise requires.
Forward-Looking
Statements
This
Current Report on Form 8-K and the information incorporated herein by reference contains forward-looking statements within the meaning
of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including with respect to the effects
of the Business Combination. These statements are based on the current expectations and beliefs of management of the Company and are
subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking
statements. These forward-looking statements include statements about future financial and operating results of the Company; statements
of the plans, strategies and objectives of management for future operations of the Company; statements regarding future economic conditions
or performance; and other statements regarding the future business of the Company. Forward-looking statements may contain words such
as “will be,” “will,” “expect,” “anticipate,” “continue,” “project,”
“believe,” “plan,” “could,” “estimate,” “forecast,” “guidance,”
“intend,” “may,” “plan,” “possible,” “potential,” “predict,”
“pursue,” “should,” “target” or similar expressions, and include the assumptions that underlie such
statements. These statements include, but are not limited to the following:
|
● |
the occurrence of any event,
change or other circumstances, including the outcome of any legal proceedings that may be instituted against the Company; |
|
|
|
|
● |
the ability to maintain
the listing of the Common Stock on the Nasdaq, as applicable; |
|
|
|
|
● |
the risk of disruption
to the Company’s current plans and operations; |
|
|
|
|
● |
the ability to recognize
the anticipated benefits of the Company’s business, which may be affected by, among other things, competition and the ability
to grow and manage growth profitably and retain its key employees; |
|
|
|
|
● |
costs related to the Company’s
business; |
|
|
|
|
● |
changes in applicable laws
or regulations; |
|
|
|
|
● |
the ability of the Company
to raise financing in the future; |
|
|
|
|
● |
the success, cost and timing
of the Company’s product development activities; |
|
|
|
|
● |
the Company’s ability
to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; |
|
|
|
|
● |
the Company’s ability
to maintain existing license agreements and manufacturing arrangements; |
|
|
|
|
● |
the Company’s ability
to compete with other companies currently marketing or engaged in the development of products and services that serve customers engaged
in proteomic analysis, many of which have greater financial and marketing resources than the Company; |
|
|
|
|
● |
the size and growth potential
of the markets for the Company’s products, and the ability of each to serve those markets, either alone or in partnership with
others; |
|
|
|
|
● |
the Company’s estimates
regarding expenses, future revenue, capital requirements and needs for additional financing; |
|
|
|
|
● |
the Company’s financial
performance; |
|
|
|
|
● |
the impact of the COVID-19
pandemic on the Company’s; and |
|
● |
other factors disclosed
under the section entitled “Risk Factors” in the Proxy Statement/Prospectus beginning on page 39 thereof, which
is incorporated herein by reference. |
The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors
and the other risks and uncertainties described in the “Risk Factors” section of the other documents filed by the
Company from time to time with the SEC. There can be no assurance that future developments affecting the Company will be those that the
Company has anticipated. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result
of new information, future events or otherwise, except as may be required under applicable securities laws.
Financial
Statements and Supplementary Data
Reference
is made to the disclosure set forth under Item 9.01 of this Current Report on Form 8-K concerning the financial statements and supplementary
data of ZyVersa’s Unaudited Condensed Consolidated Financial Statements of the Company – September 30, 2022 and 2021.
ZYVERSA’S
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The
following management’s discussion and analysis of ZyVersa’s financial condition and results of operations should be read
in conjunction with the audited annual and unaudited interim consolidated financial statements and related notes appearing elsewhere
in this proxy statement. Some of the information contained in this discussion and analysis, including information with respect to our
plans and strategy for our business and our expectations with respect to liquidity and capital resources, includes forward-looking statements.
These forward-looking statements are subject to numerous risks and uncertainties, including, but not limited to, those risks and uncertainties
described in “Risk Factors” in this proxy statement. Actual results could differ materially from the results described in
or implied by these forward-looking statements. In this section “we,” “us,” “our” and “ZyVersa”
refer to ZyVersa Therapeutics, Inc.
Components
of Results of Operations
Comparison
of the three months ended September 30, 2022 and September 30, 2021
The
following table summarizes our results of operations for the three months ended September 30, 2022 and 2021:
| |
For
the Three Months Ended September 30, | | |
Favorable | | |
| |
(in thousands) | |
2022 | | |
2021 | | |
(Unfavorable) | | |
%
Change | |
Operating expenses: | |
| | | |
| | | |
| | | |
| | |
Research and development | |
$ | 2,334 | | |
$ | 407 | | |
$ | (1,927 | ) | |
| (473.6 | %) |
General and administrative | |
| 1,062 | | |
| 1,707 | | |
| 645 | | |
| 37.8 | % |
Total Operating Expense | |
| 3,395 | | |
| 2,114 | | |
| (1,282 | ) | |
| (60.6 | %) |
| |
| | | |
| | | |
| | | |
| | |
Total Operating Loss | |
| (3,395 | ) | |
| (2,114 | ) | |
| (1,281 | ) | |
| (60.6 | %) |
| |
| | | |
| | | |
| | | |
| | |
Other Income (Expense),
Net | |
| (297 | ) | |
| 236 | | |
| (533 | ) | |
| (225.4 | %) |
| |
| | | |
| | | |
| | | |
| | |
Net loss | |
$ | (3,693 | ) | |
$ | (1,879 | ) | |
$ | (1,814 | ) | |
| (96.5 | %) |
Research
and development expenses
The
following table summarizes our research and development expenses for the three months ended September 30, 2022 and 2021:
| |
For
the Three Months Ended September 30, | | |
Favorable | | |
| |
(in thousands) | |
2022 | | |
2021 | | |
(Unfavorable) | | |
%
Change | |
Research and development | |
| | | |
| | | |
| | | |
| | |
Personnel expenses | |
$ | 166 | | |
$ | 330 | | |
$ | 164 | | |
| 49.7 | % |
Pre-clinical operations | |
| | | |
| | | |
| | | |
| | |
IC100 | |
| 30 | | |
| - | | |
| (30 | ) | |
| - | |
Drug manufacturing and formulation | |
| | | |
| | | |
| | | |
| | |
VAR200 | |
| 2 | | |
| 2 | | |
| - | | |
| 0.0 | % |
IC100 | |
| 1,928 | | |
| 19 | | |
| (1,909 | ) | |
| (10061.8 | %) |
Other costs | |
| | | |
| | | |
| | | |
| | |
VAR200 | |
| 171 | | |
| 11 | | |
| (161 | ) | |
| (1529.9 | %) |
IC100 | |
| 36 | | |
| 45 | | |
| 9 | | |
| 19.4 | % |
Total research and development | |
$ | 2,334 | | |
$ | 407 | | |
$ | (1,927 | ) | |
| (473.6 | %) |
Research
and development expenses were $2.3 million for the three months ended September 30, 2022, an increase of $1.9 million or 473% from the
three months ended September 30, 2021.
Personnel
expenses decreased by approximately $0.2 million, or 50%, to approximately $0.2 million for the three months ended September 30, 2022
from approximately $0.3 million for the three months ended September 30, 2021. The decrease in personnel expenses is primarily related
to a decrease in stock-based compensation for options granted in the prior year to consultants that immediately vested.
Pre-clinical
operations increased by approximately $30 thousand to $30 thousand for the three months ended September 30, 2022 from approximately $0.0
million for the three months ended September 30, 2021. The increase is a result of pharmacology spending occurring during the three months
ended September 30, 2022.
Drug
manufacturing and formulation increased by approximately $1.9 million to approximately $1.9 million for the three months ended September
30, 2022 from approximately $19 thousand for the three months ended September 30, 2021. The increase is driven by a $1.9 million purchase
of materials for the anticipated batch manufacturing.
Other
research and development costs increased by approximately $0.1 million to approximately $0.2 million for the three months ended September
30, 2022 from approximately $56 thousand for the three months ended September 30, 2021. The increase is driven by a consultant services.
General
and administrative expenses
The
following table summarizes our general and administrative (or, G&A) expenses for the three months ended September 30, 2022 and 2021:
| |
For
the Three Months Ended September 30, | | |
Favorable | | |
| |
(in thousands) | |
2022 | | |
2021 | | |
(Unfavorable) | | |
%
Change | |
General and administrative: | |
| | | |
| | | |
| | | |
| | |
Personnel expenses | |
$ | 772 | | |
$ | 1,474 | | |
$ | 702 | | |
| 47.6 | % |
Legal and professional fees | |
| 167 | | |
| 128 | | |
| (39 | ) | |
| (30.4 | %) |
Rent expense | |
| 42 | | |
| 37 | | |
| (6 | ) | |
| (15.0 | %) |
Other | |
| 81 | | |
| 69 | | |
| (12 | ) | |
| (18.0 | %) |
Total general and administrative | |
$ | 1,062 | | |
$ | 1,707 | | |
$ | 645 | | |
| 37.8 | % |
General
and administrative expenses were $1.1 million for the three months ended September 30, 2022, a decrease of $0.6 million
or 38% from the three months ended September 30, 2021.
Personnel
expenses decreased by approximately $0.7 million, or 48%, to approximately $0.8 million for the three months ended
September 30, 2022 from approximately $1.5 million for the three months ended September 30, 2021. The decrease in
personnel expenses is primarily related to a decrease in stock-based compensation for options granted in the prior year to a board
member and consultants that immediately vested. Legal and professional fees increased by approximately $39 thousand, or 30%, to
approximately $0.2 million for the three months ended September 30, 2022, from $0.1 million for the
three months ended September 30, 2021 due to business combination fees which are not directly related to the
transaction.
Rent
expense increased by approximately $6 thousand, or 15%, to approximately $42 thousand for the three months ended September 30,
2022 from approximately $37 thousand for the three months ended September 30, 2021.
Other
general and administrative expense increased by approximately $12 thousand, or 18%, to approximately $81 thousand for the three months
ended September 30, 2022 from approximately $69 thousand for the three months ended September 30, 2021. The increase in
other expenses is related to additional fees related to investor relations.
Other (Income) and Expense
The
following table summarizes interest and other income (expense), net for the three months ended September 30, 2022 and 2021:
| |
For
the Three Months Ended Septemer 30, | | |
Favorable | | |
| |
(in thousands) | |
2022 | | |
2021 | | |
(Unfavorable) | | |
%
Change | |
Other Expense | |
| | | |
| | | |
| | | |
| | |
Interest expense | |
$ | 69 | | |
$ | 224 | | |
$ | 155 | | |
| 69.1 | % |
Change in fair value of derivative liability | |
| 228 | | |
| (247 | ) | |
| (475 | ) | |
| (192.5 | %) |
Gain on forgiveness of PPP Loan | |
| - | | |
| (213 | ) | |
| (213 | ) | |
| (100.0 | %) |
Total Other Expense, Net | |
$ | 297 | | |
$ | (236 | ) | |
$ | (533 | ) | |
| (226.3 | %) |
Total
other expense, net was $0.3 million during the three months ended September 30, 2022, an increase of $0.5 million
or 227% compared to the three months ended September 30, 2021. The change was a result of reduced interest expense of $74 thousand
due to the conversion of the 2021 Notes in July 2022 and an increased loss from the change in the fair value of the derivative liability
of $0.5 million and other income in prior year for gain on the forgiveness of the PPP Loan of $0.2 million.
Comparison
of the nine months ended September 30, 2022 and September 30, 2021
The
following table summarizes our results of operations for the nine months ended September 30, 2022 and 2021:
| |
For the Nine Months Ended
September 30, | | |
Favorable | | |
% | |
(in thousands) | |
2022 | | |
2021 | | |
(Unfavorable) | | |
Change | |
Operating expenses: | |
| | | |
| | | |
| | | |
| | |
Research and development | |
$ | 4,120 | | |
$ | 1,490 | | |
$ | (2,630 | ) | |
| (176.5 | )% |
General and administrative | |
| 4,527 | | |
| 4,437 | | |
| (90 | ) | |
| (2.0 | )% |
Total Operating Expense | |
| 8,647 | | |
| 5,928 | | |
| (2,720 | ) | |
| (45.9 | )% |
| |
| | | |
| | | |
| | | |
| | |
Total Operating Loss | |
| (8,647 | ) | |
| (5,928 | ) | |
| (2,719 | ) | |
| (45.9 | )% |
| |
| | | |
| | | |
| | | |
| | |
Other Income (Expense), Net | |
| (798 | ) | |
| (187 | ) | |
| (611 | ) | |
| (325.3 | )% |
| |
| | | |
| | | |
| | | |
| | |
Net loss | |
$ | (9,445 | ) | |
$ | (6,115 | ) | |
$ | (3,330 | ) | |
| (54.5 | )% |
Research
and development expenses
The
following table summarizes our research and development expenses for the nine months ended September 30, 2022 and 2021:
| |
For the Nine Months Ended September 30, | | |
Favorable | | |
% | |
(in thousands) | |
2022 | | |
2021 | | |
(Unfavorable) | | |
Change | |
Research and development | |
| | | |
| | | |
| | | |
| | |
Personnel expenses | |
$ | 916 | | |
$ | 984 | | |
$ | 68 | | |
| 6.9 | % |
Clinical operations | |
| | | |
| | | |
| | | |
| | |
VAR200 | |
| (100 | ) | |
| 5 | | |
| 105 | | |
| 1965.5 | % |
Pre-clinical operations | |
| | | |
| | | |
| | | |
| | |
IC100 | |
| 60 | | |
| 161 | | |
| 101 | | |
| 62.9 | % |
Drug manufacturing and formulation | |
| | | |
| | | |
| | | |
| | |
VAR200 | |
| 8 | | |
| 22 | | |
| 16 | | |
| 67.37 | % |
IC100 | |
| 2,949 | | |
| 133 | | |
| (2,818 | ) | |
| (2149.5 | )% |
Other costs | |
| | | |
| | | |
| | | |
| | |
VAR200 | |
| 194 | | |
| 32 | | |
| (162 | ) | |
| (514.7 | )% |
IC100 | |
| 94 | | |
| 154 | | |
| 60 | | |
| 38.8 | % |
Total research and development | |
$ | 4,120 | | |
$ | 1,490 | | |
$ | (2,630 | ) | |
| (176.5 | )% |
Research
and development expenses were $4.1 million for the nine months ended September 30, 2022, an increase of $2.6 million or 176.5% from the
nine months ended September 30, 2021.
Personnel
expenses decreased by approximately $0.1 million, or 7%, to approximately $0.9 million for the nine months ended September 30, 2022 from
approximately $1.0 million for the nine months ended September 30, 2021. The decrease in personnel expenses is primarily related to a
decrease in stock-based compensation of approximately $0.1 million as a result of options granted in the prior year to consultants that
immediately vested.
Clinical
operations decreased by approximately $105 thousand, or 1966%, for the nine months ended September 30, 2022 from approximately $5 thousand
for the nine months ended September 30, 2021. The decrease in clinical operations is primarily related to a credit received from a vendor
for work that was not completed due to the COVID-19 pandemic.
Pre-clinical
operations decreased by approximately $0.1 million to $0.1 million for the nine months ended September 30, 2022 from approximately $0.2
million for the nine months ended September 30, 2021. The decrease is a result of minimal pharmacology spending occurring during the
nine months ended September 30, 2022.
Drug
manufacturing and formulation increased by approximately $2.8 million to approximately $2.9 million for the nine months ended September
30, 2022 from approximately $0.1 million for the nine months ended September 30, 2021. The increase is driven by a $2.5 million purchase
of materials for the anticipated batch manufacturing.
Other
research and development costs increased by approximately $0.1 million to approximately $0.3 million for the nine months ended September
30, 2022 from approximately $0.2 million for the nine months ended September 30, 2021. The increase is driven by a consultant services.
General
and administrative expenses
The
following table summarizes our general and administrative (or, G&A) expenses for the nine months ended September 30, 2022
and 2021:
| |
For the Nine Months Ended September 30, | | |
Favorable | | |
% | |
(in thousands) | |
2022 | | |
2021 | | |
(Unfavorable) | | |
Change | |
General and administrative: | |
| | | |
| | | |
| | | |
| | |
Personnel expenses | |
$ | 3,549 | | |
$ | 3,570 | | |
$ | 21 | | |
| 0.6 | % |
Legal and professional fees | |
| 675 | | |
| 493 | | |
| (182 | ) | |
| (36.9 | )% |
Rent expense | |
| 119 | | |
| 111 | | |
| (8 | ) | |
| (6.8 | )% |
Other | |
| 185 | | |
| 264 | | |
| 79 | | |
| 30.2 | % |
Total general and administrative | |
$ | 4,527 | | |
$ | 4,437 | | |
$ | (90 | ) | |
| (2.0 | )% |
General
and administrative expenses were $4.5 million for the nine months ended September 30, 2022, an increase of $0.1 million or 2% from the
nine months ended September 30, 2021.
Personnel
expenses decreased by approximately $21 thousand, or 0.6%, to approximately $3.5 million for the nine months ended September 30, 2022
from approximately $3.6 million for the nine months ended September 30, 2021.
Legal
and professional fees increased by approximately $0.2 million, or 37%, to approximately $0.7 million for the nine months ended September
30, 2022, from $0.5 million for the nine months ended September 30, 2021 due to business combination fees which are not directly related
to the transaction.
Rent
expense increased by approximately $8 thousand, or 7%, to approximately $119 thousand for the nine months ended September 30, 2022 from
approximately $111 thousand for the nine months ended September 30, 2021.
Other
general and administrative expense decreased by approximately $79 thousand, or 30%, to approximately $185 thousand for the nine months
ended September 30, 2022 from approximately $264 thousand for the nine months ended September 30, 2021. The decrease in other expenses
is primarily related to approximately $50 thousand reduction in advisory service fees in addition to approximately $20 thousand in board
fees due to the retirement of the chairman of the board of directors.
Other
(Income) and Expense
The
following table summarizes interest and other income (expense), net for the nine months ended September 30,
2022 and 2021:
| |
For the Nine Months Ended September 30, | | |
Favorable | | |
% | |
(in thousands) | |
2022 | | |
2021 | | |
(Unfavorable) | | |
Change | |
Other Expense | |
| | | |
| | | |
| | | |
| | |
Interest expense | |
$ | 378 | | |
$ | 617 | | |
$ | 239 | | |
| (38.7 | )% |
Change in fair value of derivative liability | |
| 421 | | |
| (216 | ) | |
| (637 | ) | |
| (294.8 | )% |
Gain on forgiveness of PPP Loan | |
| - | | |
| (213 | ) | |
| (213 | ) | |
| (100.0 | )% |
Total Other Expense, Net | |
$ | 798 | | |
$ | 187 | | |
$ | (611 | ) | |
| (325.3 | )% |
Total
other expense, net was $0.8 million during the nine months ended September 30, 2022, an increase of $0.6 million or 326% compared to
the nine months ended September 30, 2021. The change was a result of reduced interest expense of $0.4 million due to the conversion
of the 2021 Notes in July 2022 and an increased loss from the change in the fair value of the derivative liability of $0.6 million
and other income in prior year for gain on the forgiveness of the PPP Loan of $0.2 million.
Cash
Flows
The
following table summarizes our cash flows from operating, investing and financing activities for the nine months ended September 30,
2022 and 2021:
| |
September 30, | | |
Increase | |
(in thousands) | |
2022 | | |
2021 | | |
(decrease) | |
Net cash provided by (used in) | |
| | | |
| | | |
| | |
Operating activities | |
$ | (1,078 | ) | |
$ | (4,460 | ) | |
$ | 3,382 | |
Financing activities | |
$ | 1,353 | | |
$ | 5,230 | | |
| (3,877 | ) |
Cash
Flows from Operating Activities
Net
cash used in operating activities for the nine months ended September 30, 2022 and 2021 was approximately $1.1 million and $4.5 million,
respectively. During the nine months ended September 30, 2022 and 2021, the net cash used in operating activities was primarily attributable
to the net loss from continuing operations of approximately $9.4 million and $6.1 million, respectively, offset by $3.6 million and $3.2
million, respectively, of net non-cash expenses the majority of which was driven by stock based compensation, and approximately $4.8
million and ($1.5) million, respectively, of cash provided by/(used in) changes in the levels of operating assets and liabilities, respectively.
Net
Cash Provided by Financing Activities
Net
cash provided by financing activities for the nine months ended September 30, 2022 was approximately $1.4 million compared to approximately
$5.2 million for the nine months ended September 30, 2021. Cash provided by financing activities during the nine months ended September
30, 2022 represented proceeds from the issuance of preferred stock in private placement of $1.4 million. During the nine months ended
September 30, 2021, we received $5.2 million of proceeds from the issuance of convertible notes payable.